Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

(2017) Nicole M. Piche-Nicholas et al.   mAbs

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

(2017) Miroslav Dostalek et al.   mAbs

Biophysical properties of the clinical-stage antibody landscape

(2017) Tushar Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

(2016) Lindsay B. Avery et al.   mAbs

Target-independent variable region mediated effects on antibody clearance can be FcRn independent

(2016) Ryan L. Kelly et al.   mAbs

Measurements of Monoclonal Antibody Self-Association Are Correlated with Complex Biophysical Properties

(2016) Steven B. Geng et al.   MOLECULAR PHARMACEUTICS

Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo

(2016) Claire L. Dobson et al.   Scientific Reports

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics

(2015) Daniela Bumbaca Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Developability Assessment During the Selection of Novel Therapeutic Antibodies

(2015) Alexander Jarasch et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice

(2015) Ryan L Kelly et al.   mAbs

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

(2015) Amita Datta-Mannan et al.   mAbs

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

(2015) Amita Datta-Mannan et al.   mAbs

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

(2015) Angela Schoch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy

(2015) Jiemin Wu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

(2014) M. Jack Borrok et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

(2014) Bing Li et al.   mAbs

One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics

(2014) Alison P. Joyce et al.   PHARMACEUTICAL RESEARCH

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

(2013) Tilman Schlothauer et al.   mAbs

High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy

(2013) Yuqi Liu et al.   mAbs

Rapid Analysis of Antibody Self-Association in Complex Mixtures Using Immunogold Conjugates

(2013) Shantanu V. Sule et al.   MOLECULAR PHARMACEUTICS

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool

(2013) Y. Xu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Embryo-Fetal Transfer of Bevacizumab (Avastin) in the Rat Over the Course of Gestation and the Impact of Neonatal Fc Receptor (FcRn) Binding

(2012) Mitchell Thorn et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

A strategy for risk mitigation of antibodies with fast clearance

(2012) Isidro Hötzel et al.   mAbs

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

(2011) Jennifer Q. Dong et al.   CLINICAL PHARMACOKINETICS

Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

(2011) W. Wang et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data

(2011) Masataka Oitate et al.   Drug Metabolism and Pharmacokinetics

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

(2010) Bing-Bing Yang et al.   CLINICAL PHARMACOKINETICS

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Reduced elimination of IgG antibodies by engineering the variable region

(2010) T. Igawa et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Tocilizumab

(2009) Vicki Oldfield et al.   DRUGS

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

(2009) Jie Ling et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

(2007) Thomas Tiller et al.   JOURNAL OF IMMUNOLOGICAL METHODS